Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab plus erlotinib vs erlotinib alone in EGFR-mutated advanced non-squamous NSCLC (phase 3)
2015-002235-17Phase 3Active
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Sep 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Bevacizumab + erlotinib with Erlotinib alone (2 arms). Primary endpoint: Investigator-assessed progression-free survival. Started Sep 2021; status: active.
02
Drugs
bevacizumaberlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2015-002235-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002235-17.